Medtronic (Minneapolis) is reporting that its pivotal trial in renal denervation for treatment-resistant hypertension, the SYMPLICITY HTN-3, has failed to meet its primary efficacy endpoint and that it suspending enrollment in other SYMPLICITY trials around the world. Read More
